Sign in
CVM Stock Price, Chart, Stats & News
CEL-SCI Corporation
Save
CEL-SCI Corporation (CVM) does not currently pay a dividend.
–
Market cap
–
Current P/E
23.04x
Forward P/E
CVM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -103.99% |
ROE | -226.10% |
D/E | 0.95x |
Interest coverage ratio | -41.09x |
CVM valuation
P/E | – |
P/S | – |
P/B | 2.30x |
P/CF | -1.51x |
P/FCF | -1.29x |
P/OCF | -1.51x |
PEG | -0.03x |
EV multiple | -0.91x |
About
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology.
Similar securities
Based on sector and market capitalization
Report issue